VIZIENT, INC. for VIZIENT INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
21st Century Next-Generation Cures Initiative: Responded to congressional request for information (RFI) on biomedical research and innovation. Encouraged Congress to consider whether use of the Vizient Vulnerability Index is appropriate as stakeholders consider innovative approaches to advance further technological progress. CMS Medicare Drug Price Negotiation Program: Draft Guidance - Encouraged CMS to consider minimizing provider burden, including avoiding disruptions to current purchasing and reimbursement practices; urged CMS to avoid final guidance that enables a retrospective payment of the 340B discount. Issues related to hospital and provider payment. Issues related to pharmacy benefit managers; monitoring the Modernizing and Ensuring PBM Accountability (MEPA) Act (S.2973). Lower Costs, More Transparency Act (H.R. 5378) - Opposed adoption of site-neutral payment policies for drug administration and increased fines related to price transparency requirements for hospitals. Urged Congress to redirect its focus from site-neutral payment policies to reducing administrative burdens and increasing, rather than reducing, payments for care delivery in rural areas. Medicare and Medicaid Programs; CMS CY 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment Systems proposed rule (CMS-1809-P) - Responded to various issues and proposals provided in the Proposed Rule and offered our responses to the agencys various requests for information. Medicare and Medicaid Programs; CMS CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments proposed rule - Responded to various issues and proposals provided in the Proposed Rule and offered our responses to the agencys various requests for information. Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current 2024 expiration date.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDRIA LEIGH ICENHOWER | — |
| SHOSHANA KRILOW | — |
| JENNA STERN | — |
| DARREN WEBB | — |
Health Issues HCR
340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. Buffer inventory - Engagements with CMS on reimbursement for hospitals that stockpile buffer supplies of essential medicines. Children's Hospital Graduate Medical Education (CHGME) - Continued to urge Congress to reauthorize CHGME program through the Childrens Hospital GME Support Reauthorization Act of 2023 (H.R. 3887). Offered support for providing $738 million in funding the CHGME program. Drug shortages -Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Continued supporting passage of The Drug Shortage Prevention Act (H.R. 3008) and The Drug Origin Transparency Act (H.R. 3810). Provided feedback on the Senate Finance Committee discussion draft on the Drug Shortage Prevention and Mitigation Act (No Bill Number) legislation. Healthcare Workforce - Monitored development of the Bipartisan Primary Care and Health Workforce Act (S.2840) and the Safety from Violence for Healthcare Employees (SAVE) Act (H.R. 2584/S. 2768). Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Interchangeability Status - Responded to the Food and Drug Administration (FDA) draft guidance on Considerations for Demonstrating Interchangeability with a Reference Product: Update. Urged FDA to promptly finalize the Draft Guidance. Medical Device Sterilization - Conducted education and outreach on the potential negative impact on the healthcare supply chain of pending regulations limiting the use of Ethylene Oxide as a medical device sterilant. Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications. Social Determinants of Health - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand and identify social drivers of health at the neighborhood level. Telehealth - Continued supporting passage of the CONNECT for Health Act (S. 2016/H.R. 4189). Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current 2024 expiration date. Telemedicine prescribing - Encouraged Congress to pass a two-year extension of Drug Enforcement Administration (DEA) prescribing flexibilities without requiring an in-person medical evaluation. Workforce - Encouraged passage of The Health Workforce Innovation Act (S.4957).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDRIA LEIGH ICENHOWER | — |
| SHOSHANA KRILOW | — |
| JENNA STERN | — |
| DARREN WEBB | — |
Taxation/Internal Revenue Code TAX
Not-for-Profit Hospital Tax-exemption - Provided education and information on hospital tax exemption and what is required to justify and maintain tax-exempt status.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDRIA LEIGH ICENHOWER | — |
| SHOSHANA KRILOW | — |
| JENNA STERN | — |
| DARREN WEBB | — |
Tariff (miscellaneous tariff bills) TAR
Sec. 301 China Tariffs - Continued to advocate for clarity around the expiration of tariff exclusions for products necessary to respond to the COVID-19 pandemic. Supported extending exclusions for key healthcare products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDRIA LEIGH ICENHOWER | — |
| SHOSHANA KRILOW | — |
| JENNA STERN | — |
| DARREN WEBB | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.